Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 18Glioma 11Neoplasms 6Brain Neoplasms 6Astrocytoma 6Neuroblastoma 4Sarcoma, Ewing 3Gliosarcoma 3Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Medulloblastoma 2Diffuse Intrinsic Pontine Glioma 2Wilms Tumor 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Refractory Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma, Follicular 1Hepatoblastoma 1Ganglioneuroblastoma 1

Interventions

abemaciclib 1Temozolomide 1Radiosurgery 1Clinical Laboratory Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spinal Cord Neoplasms × Temozolomide × 30 days × Clear all
NCT06413706 2026-05-22

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Eli Lilly and Company

Phase 2 Active not recruiting
45 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡